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doi:10.1016/j.fjs.2012.01.007Summary Primary breast neuroendocrine carcinoma (BNEC) is rare. High-grade BNEC, such
as small cell carcinoma and large cell carcinoma, sometimes exhibits specific histological
features, and is easily diagnosed. Low-grade solid BNEC, however, may demonstrate no specific
neuroendocrine features on histological examination, which serve to distinguish it from
conventional invasive carcinoma. Here, we present the case of a 46-year-old woman who
was suspected of having BNEC. Suspicion was initially aroused by crush artifact during the time
of frozen section. Subsequent immunohistochemistry established the diagnosis of solid BNEC
according to the criteria of the WHO definition.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In 2003, the World Health Organization (WHO) defined
breast neuroendocrine carcinoma (BNEC) as a unique
category of breast cancer. The diagnosis of BNEC required
immunohistochemical (IHC) expression of neuroendocrine
(NE) markers in more than 50% of breast tumors. The WHO
also divided the BNECs into 3 subclasses, consisting of solid
neuroendocrine carcinoma, small/oat cell carcinoma andof Anatomic Pathology, New
gshan Road, Sanchong City,
net.net (P.-H. Huang).
ight ª 2012, Taiwan Surgical Assolarge cell neuroendocrine carcinoma.1 Primary BNEC is
a rare breast cancer, and the reported data vary from
< 0.1% to 5% of all breast cancers.2e6 BNECs have multidi-
rectional differentiation in morphology, including mucinous
differentiation, overlapping in expression usual types of
breast carcinoma.4 Here we present a case of solid BNEC
diagnosed based on subtle histological characteristics and
specific IHC expressions.
2. Case report
A 46-year-old woman, who had smoked for 20 years, had
a right breast lump for 2 weeks. She underwent breast
ultrasonography, which showed a heterogenous and hypo-
echoic mass about 2 cm in diameter, without calcificationciation. Published by Elsevier Taiwan LLC. All rights reserved.
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position, 5 cm from the right nipple. Routine blood, urine
biochemistry, CEA and CA153 examinations were within
normal limits. She had a biopsy taken after ultrasonography
and the subsequent frozen section of the breast lesion
revealed malignant cells with crushed, obscured nuclear
contours, arranged in irregular sheets against a dense
fibrous background. A modified radical mastectomy with
lymph node dissection was performed. The histological
features of the tumor were similar to those of a usual
invasive duct carcinoma, and histologically were grade II
with scant tubular formation, intermediate-sized nuclei
and rare mitoses. Nevertheless, the presence of a marked
crush artifact of tumor cells in the frozen section, small
monotonous tumor cells and rare mitoses of the infiltrating
tumor aroused suspicion of a neuroendocrine nature. The
tumor also contained a low-grade duct carcinoma in situ
lesion (Fig. 1). IHC studies showed the tumor cells to be
positive for both the estrogen receptor (ER) and proges-
terone receptor (PR) and negative for Her-2. The tumor
exhibited, in addition, an IHC reaction to synaptophysin,
chromogranin A, neurone-specific enolase (NSE) and CD56,
and was thus shown to be a solid neuroendocrine carcinoma
of the breast (Fig. 2). All 13 dissected axillary lymph nodes
were free from metastasis and the post-operative
computerized tomogram showed no secondary or remain-
ing tumor in the body.Figure 1 (A) Frozen section of breast tumor showing infiltrating
toxylin and eosin, 200 ); (B) low-power histologic features of tumo
from crush (hematoxylin and eosin, 100 ); (C) under magnification
monotonous nuclei and scant mitoses about 0e2/10 HPF (hemato
lesion contained in specimen (hematoxylin and eosin, 100 ).Postoperatively, the patient received oral tamoxifen
chemotherapy only. There were no signs of recurrence 6
months after the surgical procedure.3. Discussion
Since Cubilla and Woodruff first described seven cases of
breast carcinoid tumor with NE secretory activity in 1977,
BNEC has become a distinct topic of breast cancer. In 1982,
Azzapardi presented 14 cases of breast carcinoid tumors
in which he noticed a wide range of morphological and
histochemical appearances and a variable prognosis. These
breast carcinoid tumors had 18% of nodal or distant
metastases, which occurred only when the tumor was
2.5 cm or larger and with ten or more mitoses/10HPF.5 The
breast carcinoid tumors (now called neuroendocrine carci-
noma) with high mitotic figures are classified into interme-
diate differentiated BNEC, such as alveolar carcinoma
based on WHO classification.3 Recent studies demonstrated
that the low-grade BNECs, such as solid BNECs, have a low
percentage of lymph node metastasis and a low rate of
recurrence and metastasis.4,5,7,8 Some BNECs with
mucinous differentiation have also been shown to have good
prognosis.1,4,8,9,12 Most BNECs, except small cell carcinoma
and large cell carcinoma, have a better prognosis than the
usual invasive breast cancers.1,4,5tumor nests with marked crush artifact of tumor cells (hema-
r, similar to those of a usual invasive ductal carcinoma, but free
, the tumor cells were shown to have intermediate size, rather
xylin and eosin, 400 ); (D) low-grade duct carcinoma in situ
Figure 2 The breast tumor cells were reactive to: (A) estrogen receptor; (B) progesterone receptor. Tumor cells (80%) were
reactive to Synaptophysin (C) and 60% were reactive to Chromogranin A (D).
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neuroendocrine markers in > 50% of the cell population,
and the expression should be positive for at least two of the
following markers: chromogranin A, synaptophysin, CD56
(NCAM) and NSE.1,4 Our case had IHC expression in 100% of
NSE, 80% of synaptophysin and 60% of chromogranin A,
correlated with the definition of BNEC. A breast tumor with
focal and scattered IHC NE staining should be regarded as
a tumor with endocrine differentiation, but not a BNEC.1,4
Both the ER and PR expressions of our case were similar
to those of most well differentiated BNECs,4e8 which indi-
cates a good prognosis.8
Morphologically, most helpful diagnostic features of
a solid BNEC are nuclear palisading, rosette formation,
cellular monotony and presence of an intraductal carcinoma
in situ component. The presence of intracellular or extra-
cellular mucin, or both, in tumor cells could also be features
of mucinous BNEC.4,9 However, most solid BNECs lack those
specific features and might histologically overlap with
conventional types of breast carcinoma. It is noticeable that
only three of nine BNEC cases with features of invasive breast
carcinoma, revealed those unique NE histological features in
a study by Cai and Seng.4 Our case demonstrated no specific
NE histological features, except for a marked crush artifact
in the frozen section, which disappeared in the permanent
section. The cellular monotony and rare mitoses also
should provoke suspicion of a NE tumor. The crush artifact
can occur in both low-grade and high-grade NE neoplasms.10
A crush artifact found in either the frozen section, cytologypreparation or permanent sections of breast tumor should
alert one to be the possibility of BNEC tumor.
Most patients cited in literature concerning BNEC are
women in the 6th and 7th decades of life.1,11 The mean age
of BNEC is 66 years (range: 35e97 years) in a series of 38
cases studied by Upalakalin et al11 and 66.5 years (range:
43e79 years) in a series of 13 cases studied by Cai and
Seng.4 Although the mean age is in the 7th decade, the
disease may occur in the younger age group. Several case
reports of solid BNEC, including ours, contain patients of
a younger age, e.g., 46 years, 41 years,5 34 years2 and 40
years.7 This might indicate that solid BNEC could occur at
a much younger age.
The percentages of BNEC among breast cancers are
variable. Lopez-Bonet et al found only 7 BNEC cases in 1368
breast cancers (0.5%), screening first for neuroendocrine
histological features, then with IHC stains for proof.6 Righi
et al estimated BNEC to constitute about 1% of all breast
carcinomas.3 Cai and Seng performed a screening test with
IHC in all 410 breast cancers and found 13 BNECs (3.2%).4
Recognition of the variable histological expressions and
wide application of IHC could improve the diagnosis of BNEC.
Overall, BNECs, especially of the solid type, show a less
aggressive clinical behavior when compared with unse-
lected breast cancers.4,8 The prognosis of BNEC depends on
the stage, tumor size and lymph node status, similar in
patterns to those of usual breast cancer.5 It may become
necessary to distinguish BNEC from conventional breast
cancer. As there has only been one previous case report of
106 P.-H. Huang et al.mucinous BNEC in Taiwan,9 the incidence of BNEC seems to
be greatly underestimated on this island.References
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